A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).
机构：[1]Fudan University Shanghai Cancer Center, Shanghai, China[2]Jiangsu Provincial People’s Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, China江苏省人民医院[3]The First Affiliated Hospital of Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[4]2nd Affiliated Hospital of Nanchang University, Nanchang, China[5]Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[6]Liaoning Cancer Hospital and Institute, Shenyang, China[7]Department of Radiotherapy and Oncology, Second Affiliated Hospital of Soochow University, Suzhou, China苏州大学附属第二医院[8]Guizhou Cancer Hospital, The Affiliated Cancer Hospital of Guiyang Medical College, Guiyang, China[9]1st Affiliated Hospital of Soochow University, Suzhou, China[10]Ningbo No.2 Hospital, Ningbo, China[11]West China Hospital Sichuan University, Chengdu, China四川大学华西医院[12]Shanghai Ruijin Hospital, Shanghai, China[13]Hubei Cancer Hospital, Wuhan, China[14]Fujian Cancer Hospital, Fuzhou, China[15]Sichuan Cancer Hospital and Institute, Chengdu, China四川省肿瘤医院[16]Shanghai Cancer Center, Fudan University, Shanghai, China
第一作者机构：[1]Fudan University Shanghai Cancer Center, Shanghai, China[2]Jiangsu Provincial People’s Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, China[3]The First Affiliated Hospital of Chongqing Medical University, Chongqing, China[4]2nd Affiliated Hospital of Nanchang University, Nanchang, China[5]Zhejiang Cancer Hospital, Hangzhou, China[6]Liaoning Cancer Hospital and Institute, Shenyang, China[7]Department of Radiotherapy and Oncology, Second Affiliated Hospital of Soochow University, Suzhou, China[8]Guizhou Cancer Hospital, The Affiliated Cancer Hospital of Guiyang Medical College, Guiyang, China[9]1st Affiliated Hospital of Soochow University, Suzhou, China[10]Ningbo No.2 Hospital, Ningbo, China[11]West China Hospital Sichuan University, Chengdu, China[12]Shanghai Ruijin Hospital, Shanghai, China[13]Hubei Cancer Hospital, Wuhan, China[14]Fujian Cancer Hospital, Fuzhou, China[15]Sichuan Cancer Hospital and Institute, Chengdu, China[16]Shanghai Cancer Center, Fudan University, Shanghai, China
推荐引用方式(GB/T 7714)：
Zhu Ji,Sun Xinchen,Zhang Tao,et al.A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).[J].JOURNAL OF CLINICAL ONCOLOGY.2017,35:doi:10.1200/JCO.2017.35.15_suppl.TPS3632.
APA：
Zhu, Ji,Sun, Xinchen,Zhang, Tao,Liu, Anwen,Zhu, Yuan...&Zhang, Zhen.(2017).A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare)..JOURNAL OF CLINICAL ONCOLOGY,35,
MLA：
Zhu, Ji,et al."A randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare).".JOURNAL OF CLINICAL ONCOLOGY 35.(2017)
医学